CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $25,760,700 | +125.7% | 630,000 | +133.3% | 0.40% | +129.5% |
| Q1 2024 | $11,412,900 | -42.1% | 270,000 | -41.9% | 0.17% | -34.7% |
| Q4 2023 | $19,716,000 | +1620.3% | 465,000 | +785.7% | 0.26% | +1372.2% |
| Q3 2023 | $1,146,075 | -39.9% | 52,500 | -12.5% | 0.02% | -47.1% |
| Q2 2023 | $1,907,400 | +56.4% | 60,000 | +20.0% | 0.03% | +41.7% |
| Q1 2023 | $1,219,500 | -23.7% | 50,000 | -1.4% | 0.02% | -4.0% |
| Q4 2022 | $1,599,078 | -12.1% | 50,700 | -26.3% | 0.02% | 0.0% |
| Q2 2022 | $1,819,000 | -24.8% | 68,800 | -0.3% | 0.02% | -13.8% |
| Q1 2022 | $2,419,000 | -33.9% | 69,000 | -38.8% | 0.03% | -29.3% |
| Q4 2021 | $3,657,000 | +125.5% | 112,800 | +105.1% | 0.04% | +115.8% |
| Q3 2021 | $1,622,000 | – | 55,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |